Literature DB >> 7957500

Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS).

P Cremer1, D Nagel, B Labrot, H Mann, R Muche, H Elster, D Seidel.   

Abstract

Based on pathophysiological findings Lp(a) is considered to be a cardiovascular risk factor. The Göttingen Risk Incidence and Prevalence Study (GRIPS) provides the possibility to evaluate this impact of Lp(a) on the basis of a large prospective cohort study. GRIPS included 6002 men, aged 40-59.9 years at baseline. Data of a 5 year follow-up period is now available for > 95% of the study participants. Multivariate logistic regression models for the estimation of MI risk confirm Lp(a) as an important risk factor, ranking fifth behind LDL cholesterol, family history of MI, plasma fibrinogen and HDL cholesterol (inversely related). The GRIPS data strongly support strategies for the identification and treatment of persons at increased MI risk which focus on LDL cholesterol. However, Lp(a) and fibrinogen have to be seriously considered as additional risk factors and should be included in diagnostic panels for the estimation of MI risk.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957500     DOI: 10.1111/j.1365-2362.1994.tb02373.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  28 in total

1.  Clinical implications of elevated lipoprotein(a).

Authors:  A von Eckardstein; G Assmann
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

Review 2.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

Review 3.  Novel serologic markers of cardiovascular risk.

Authors:  Guilherme H M Oliveira
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

Review 4.  Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.

Authors:  J C Adkins; D Faulds
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

5.  ENDOTHELIN-1 SYTEM ACTIVITY IN ADULTS WITH BORDERLINE HIGH LDL-CHOLESTEROL.

Authors:  Kyle J Diehl; Brian L Stauffer; Jared J Greiner; Christopher A DeSouza
Journal:  Artery Res       Date:  2014-09-01       Impact factor: 0.597

6.  [Age related decrease of high density lipoproteins (HDL) in women after menopause. Quantification of HDL with genetically determined HDL arylesterase in women with healthy coronary vessels and in women with angiographically verified coronary heart disease].

Authors:  J M Chemnitius; H Winkel; I Meyer; K Schirrmacher; V W Armstrong; H Kreuzer; R Zech
Journal:  Med Klin (Munich)       Date:  1998-03-15

Review 7.  [The role of endothelial function for ischemic manifestations of coronary atherosclerosis].

Authors:  M Britten; V Schächinger
Journal:  Herz       Date:  1998-03       Impact factor: 1.443

8.  HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?

Authors:  Claudia Stefanutti; Claudia Morozzi
Journal:  Blood Transfus       Date:  2016-06-29       Impact factor: 3.443

Review 9.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

10.  Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.

Authors:  Beate R Jaeger; Yvonne Richter; Dorothea Nagel; Franz Heigl; Anja Vogt; Eberhard Roeseler; Klaus Parhofer; Wolfgang Ramlow; Michael Koch; Gerd Utermann; Carlos A Labarrere; Dietrich Seidel
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.